期刊
EMBO MOLECULAR MEDICINE
卷 7, 期 9, 页码 1090-1103出版社
WILEY
DOI: 10.15252/emmm.201504395
关键词
cardiomyocytes; disease modeling; genome editing; human induced pluripotent stem cells; tissue engineering
资金
- National Institute of Health T32 training grant
- American Heart Association [13EIA14420025]
- NIH [R01 HL123968, R01 HL126527]
- CIRM [DR2A-05394, TR3-05556]
Heart disease remains a leading cause of mortality and a major worldwide healthcare burden. Recent advances in stem cell biology have made it feasible to derive large quantities of cardiomyocytes for disease modeling, drug development, and regenerative medicine. The discoveries of reprogramming and transdifferentiation as novel biological processes have significantly contributed to this paradigm. This review surveys the means by which reprogramming and transdifferentiation can be employed to generate induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and induced cardiomyocytes (iCMs). The application of these patient-specific cardiomyocytes for both invitro disease modeling and invivo therapies for various cardiovascular diseases will also be discussed. We propose that, with additional refinement, human disease-specific cardiomyocytes will allow us to significantly advance the understanding of cardiovascular disease mechanisms and accelerate the development of novel therapeutic options.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据